Hepatotoxicity of chemotherapy

Oncologist

Volumn 6, Issue 2, 2001, Pages 162-176

  King, Paul D ^a   Perry, Michael C ^a,b  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Cancer therapy; Chemotherapy; Hepatotoxicity; Liver function

Indexed keywords

ALDOPHOSPHAMIDE; ALKYLATING AGENT; ANALGESIC AGENT; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC ANTIBIOTIC; AZATHIOPRINE; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; FLUCONAZOLE; FLUOROURACIL; FLUTAMIDE; IFOSFAMIDE; LOMUSTINE; MEGESTROL ACETATE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NITROSOUREA DERIVATIVE; PLATINUM DERIVATIVE; STREPTOZOCIN; TAMOXIFEN; TIOGUANINE; UNINDEXED DRUG;

ARTICLE; DOSE LIVER FUNCTION RELATION; HUMAN; LIVER FUNCTION; LIVER TOXICITY; PRIORITY JOURNAL; TOXIC HEPATITIS; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; NEOPLASMS;

EID: 0035044891     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-2-162     Document Type: Article

References (197)

1. Morphologic spectrums of drug-induced liver disease
2. Criteria of drug-induced liver disorders: Report of an international consensus meeting
3. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis
4. Evaluation of abnormal liver enzyme results in asymptomatic patients
5. Drug-induced hepatotoxicity
6. Drug elimination in chronic liver diseases
7. Antecedent liver disease and drug toxicity
8. Chemotherapeutic agents and hepatotoxicity
9. Hepatotoxic effects of oncotherapeutic and immunosuppressive agents
10. The effects of impaired liver function on the elimination of antineoplastic agents
11. Hepatic toxicity of drugs used for hematologic neoplasia
12. Intestinal and liver toxicity of antineoplastic drugs
13. Antineoplastic agents and the liver
14. Drug induced liver disease: Pathogenetic mechanisms and histopathological lesions
15. Massive hepatic necrosis after cyclophosphamide
16. Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide
17. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus
18. Cyclophosphamide associated hepatotoxicity
19. Cyclophosphamide induced hepatotoxicity in a patient with Wegener's granulomatosis
20. Cyclophosphamide induced liver necrosis: A possible interaction with azathioprine
21. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation in the treatment of refractory cancer
22. Phase II trial of high dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma
23. Liver damage after chemotherapy for leukemia and lymphoma
24. Hepatotoxicity due to chlorambucil. Report of a case
25. Busulfan induced hepatitis
26. Jaundice after treatment of leukemia with busulfan
27. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by Adriamycin and 1,3 chloroethyl-nitrosurea (BCNU)
28. Clinical trials with 1,3-bis (2-chloroethyl)-nitrosourea, NSC-409962
29. CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer
30. Pancreatic islet cell carcinoma II: Results of therapy with streptozotocin in 52 patients
31. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998)
32. Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults
33. Cytosine arabinoside induced liver damage: Histopathologic demonstration
34. Hepatic dysfunction and jaundice following high-dose cytosine arabinoside
35. Pharmacology and toxicity of high dose cytarabine by 72-hour continuous infusion
36. Cytabarine
37. Clinical studies: Phase I II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia
38. 5-Fluorouracil given once weekly: Comparison of intravenous and oral administration
39. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine
40. Liver pathology following hepatic arterial infusion chemotherapy: Hepatic toxicity with FUDR
41. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma
42. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases
43. Fatal liver cirrhosis associated with long term arterial infusion of floxuridine
44. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump
45. Status of infusion chemotherapy for the treatment of liver metastases
46. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial
47. Intra arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer: A randomized trial
48. Hepatotoxicity of mercaptopurine
49. Hepatotoxicity of mercaptopurine
50. The toxic effects of 6-mercaptopurine and related compounds
51. Summary of experience with 6-mercaptopurine
52. Hepatitis in association with prolonged 6-mercaptopurine therapy
53. Toxic complications of treatment with 6-mercaptopurine. Two cases with hepatic necrosis and intestinal ulceration
54. A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors
55. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity
56. Azathioprine
57. Treatment of psoriasis with azathioprine
58. Probable azathioprine hepatotoxicity: A case report
59. Sclerosing hepatitis and azathioprine
60. Veno-occlusive disease of the liver after chemotherapy of acute leukemia
61. 6-Thioguanine as a cause of toxic veno-occlusive disease of the liver
62. Hepatic veno-occlusive disease caused by 6-thioguanine
63. Reversible hepatic veno-occlusive disease and 6 thioguanine
64. Case report: Peliosis hepatis induced by 6-thioguanine administration
65. Evaluation of two antineoplastic agents: Pipobroman (Vercyte) and thioguanine
66. Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC 740) in man
67. Hepatic fibrosis in children with acute leukemia after therapy with folic acid antagonists
68. Methotrexate hepatotoxicity in children with leukemia
69. Hepatic fibrosis in children with acute leukemia: A complication of therapy
70. Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease
71. Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood
72. Liver injury associated with methotrexate therapy for psoriasis
73. Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis
74. Methotrexate and the liver
75. A prospective study of the effects of weekly oral methotrexate on liver biopsy
76. Hepatoma in a child with methotrexate induced hepatic fibrosis
77. Hepatocellular carcinoma in a long term survivor of acute lymphocytic leukemia
78. Adriamycin chemotherapy. Efficacy, safety, and pharmacologic basis of an intermittent single high dose schedule
79. Gemcitabine - A safety review
80. Hepatic injury during doxorubicin therapy
81. Mitoxantrone: A new anti-cancer drug with significant clinical activity
82. Mitoxantrone and hepatic toxicity
83. A clinical review of bleomycin. A new antineoplastic agent
84. Mitomycin C: A review
85. Hepatotoxicity of cytostatic drugs evaluated by liver function tests and appearance of jaundice
86. Mithramycin in the treatment of disseminated testicular neoplasms
87. Metabolic and toxic effects of mithramycin during tumor therapy
88. A comparison of the rate of recovery from inhibition of RNA synthesis in mouse liver and transplantable glioma
89. Hepatic toxicity of low doses of mithramycin in hypercalcemia
90. Liver irradiation in children: Acute changes with transient leukopenia and thrombocytopenia
91. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH
92. Hepatotoxicity of actinomycin-D
93. Hepatotoxicity following vincristine therapy
94. Can severe vincristine neurotoxicity be prevented?
95. Taxanes: A new class of antitumor agents
96. Etoposide (VP-16)
97. Etoposide (VP-213) induced hepatitis. Report of three cases following standard-dose treatments
98. Etoposide induced hepatic injury: A potential complication of high-dose therapy
99. Highdose VP-16 with intermediate dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia
100. Phase II studies of dianhydrogalactitol and VP-213
101. Topoisomerase inhibitors
102. Topoisomersase I inhibitors: Topotecan and irinotecan
103. A case of liver toxicity following cis-diammine dichloroplatinum (II) treatment
104. Clinical studies of platinum coordination compounds in the treatment of various malignant diseases
105. Cisplatin-induced hepatic toxicity
106. Fatal thrombocytopenia and liver failure associated with carboplatin therapy
107. L-Asparaginase: Therapeutic and toxic effects in patients with neoplastic disease
108. L-Asparaginase
109. Toxicity of E. coli L-asparaginase in man
110. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkin's lymphomas
111. Clinical pharmacology of cancer chemotherapy
112. Drug-induced granulomatous hepatitis
113. A phase I study of hydroxyurea
114. Hydroxyurea induced hepatitis
115. Allergy-induced hepatic toxicity associated with dacarbazine
116. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma
117. Hepatic veno-occlusive disease due to DTIC
118. Phase I-II trial of lymphoblastoid interferon in metastatic malignant melanoma
119. Hepatic vascular lesions associated with dacarbazine treatment
120. Interferons in the treatment of human cancer
121. Clinical toxicity of interferons in cancer patients
122. Clinical and phase I-II studies: Treatment of renal cell carcinoma with alpha (human leucocyte) interferon and vinblastine in combination
123. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C
124. Interleukin-2 induces profound reversible cholestasis: A detailed analysis in treated cancer patients
125. Mechanisms of interleukin-2 induced hepatic toxicity
126. Jaundice during methyl testosterone therapy
127. Hepatoma and peliosis hepatitis in Fanconi's anemia
128. Androgenic-anabolic steroid therapy and hepatocellular carcinoma
129. Cholestatic hepatitis following flutamide
130. Jaundice and intrahepatic cholestasis following high dose megestrol acetate for breast cancer
131. Tamoxifen associated steatohepatitis report of 3 cases
132. Hepatic veno-occlusive disease
133. Abnormal liver function in patients undergoing autologous bone marrow transplantation for hematological malignancies
134. Veno-occlusive disease of the liver after hemopoietic cell transplantation
135. Hepatic vein thrombosis after chemotherapy for histiocytoma
136. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas
137. Busulfan and venoocclusive disease of the liver
138. An analysis of hepatic veno occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation
139. Hepatic veno-occlusive disease after high-dose mitomycin and autologous bone marrow transplantation
140. High-dose alkylating agent preparative regimen with autologous bone marrow support: The Dana-Farber Cancer Institute/Beth Israel Hospital experience
141. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation
142. Pharmacokinetics of high-dose busulfan in children
143. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation
144. Fatal hepatic vascular toxicity of DTIC
145. Hepatic toxicity of DTIC
146. Acute liver dystrophy with thrombosis of hepatic veins: A fatal complication of dacarbazine treatment
147. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy
148. Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease
149. Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease
150. Fatal veno-occlusive disease of the liver following high-dose 1,3-bis (2-chloroethyl)-nitrosourea (BCNU) and autologous bone marrow transplantation
151. Veno-occlusive disease of the liver after high dose mitomycin C therapy and autologous bone marrow transplantation
152. Pathology of the liver with bone marrow transplantation
153. Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation
154. Hepatic veno-occlusive disease (VOD) in autologous bone marrow transplantation (BMT)
155. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide
156. Hepatopathythrombocytopenia syndrome: A complication of dactinomycin therapy for Wilms' tumor. A report from the United Kingdom Children's Cancer Study Group
157. Severe hepatic toxicity after treatment with vincristine and actinomycin D using single or divided dose schedules: A report from the national Wilms' Tumor Study
158. Clinicopathologic correlation of liver damage in patients treated with 6-mercaptopurine and adriamycin
159. Oesophageal varices associated with busulphan-thioguanine therapy for chronic myeloid leukaemia
160. Nodular regenerative hyperplasia of the liver in hematological disorders: A possible response to obliterative portal venopathy. A morphometric study of nine cases with a hypothesis on the pathogenesis
161. High-dose carmustine and high-dose etoposide: A treatment regimen resulting in enhanced hepatic toxicity
162. Hepatic ultrastructure in leukemic children treated with methotrexate and 6-mercaptopurine
163. Hepatotoxicity in the treatment of acute lymphoblastic leukaemia
164. Elevated serum transaminase values during therapy for acute lymphoblastic leukemia correlate with prior blood transfusion
165. Hepatic toxicity of adjuvant chemotherapy for carcinoma of the breast
166. Subclinical hepatic toxicity during chemotherapy for breast cancer
167. Drug hepatitis of cholestatic type in association with a FAC-regimen for breast cancer
168. Hepar lobatum associated with chemotherapy and metastatic breast cancer
169. Phase I trial of hepatic artery infusion of 5-deoxyuridine and 5 fluorouracil in patients with advanced hepatic malignancy: Biochemically based chemotherapy
170. Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high risk patients with carcinoma of the colon: A Southwest Oncology Group phase II pilot study
171. A new syndrome: Ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N Phosphonacetyl-aspartate (PALA)
172. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy
173. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil
174. Fatal hepatitis following irradiation and vincristine
175. Hepatopathy following irradiation and Adriamycin
176. Radiation hepatitis
177. Fatal necrosis after high-dose chemotherapy following haloalkane anesthesia
178. Fulminant hepatic failure due to allopurinol
179. Hepatitis associated with allopurinol
180. Allopurinol hepatotoxicity potentiated by tamoxifen
181. Toxic hepatitis during ketoconazole treatment
182. Hepatitis and ketoconazole therapy
183. Hepatitis and ketoconazole therapy
184. Evaluation of hepatic injury arising during fluconazole therapy
185. Jaundice with ondansetron
186. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications
187. G-CSF and liver toxicity in a patient with neuroblastoma
188. Liver damage in patients with colony-stimulating-factor-producing tumors
189. Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: Review of nine cases
190. Anthracyclines
191. Can severe vincristine neurotoxicity be prevented?
192. Paclitaxel in patients with liver dysfunction